Aster DM Q2 FY27 Revenue Up 19% to ₹2,829 Cr, Op EBITDA Rises 25% to ₹678 Cr
Aster DM Quality Care reported Q2 FY27 revenue of ₹2,829 Cr, up 19% YoY, with Op EBITDA at ₹678 Cr, up 25% YoY. Normalised PAT rose 34% to ₹281 Cr. Patient volumes increased 12% YoY. Synergies of ₹16.6 Cr were realized in the quarter.
The significant double-digit growth in key financial metrics like revenue and EBITDA, along with improvements in margins and patient volumes, has a substantial positive impact on the company's outlook.
The company reported strong year-on-year growth in revenue, operating EBITDA, and normalised PAT, indicating a positive financial performance.
Aster DM Quality Care Limited announced its unaudited financial results for the quarter and half-year ended 30 September 2026. The company reported a significant 19% year-on-year (YoY) growth in revenue for Q2 FY27, reaching ₹2,829 crore, driven by a 12% increase in patient volumes and a 4% growth in operational beds.
Operating EBITDA saw a robust 25% YoY increase, amounting to ₹678 crore, with the EBITDA margin improving by 111 basis points to 24.0%. This growth was attributed to strong topline performance, operational leverage, effective cost management, and synergy realization. Normalised Profit After Tax (PAT) grew by 34% YoY to ₹281 crore.
The company highlighted key operational metrics, including a 12% YoY rise in total patient volume to 2.18 million in Q2 FY27. Occupancy rates increased by 335 basis points to 68%. Medical Value Travel (MVT) revenue grew by 36% YoY.
Synergies realized in Q2 FY27 amounted to ₹16.6 crore, with a full synergy potential of ₹200 crore. The company has invested over ₹600 crore in medical technology in the last 18 months, enhancing its clinical capabilities. Several new Centers of Excellence (CoEs) were launched, including the ARISE Robotic Spine Institute, CARE Cancer Institute, and Fetal Medicine COE.
For the half-year ended 30 September 2026 (H1 FY27), revenue grew by 20% YoY to ₹5,429 crore, and Operating EBITDA increased by 27% YoY to ₹1,255 crore. Normalised PAT for H1 FY27 rose by 27% YoY to ₹457 crore.
The company also addressed an inadvertent typographical error in a previous presentation regarding workforce numbers, which has been rectified in the revised investor presentation. An investor call was scheduled for 6 November 2026, in relation to these results.
What to do with a filing like this
Aster DM Quality Care Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Quality Care Limited. Read the original for the full detail.